Trials Sponsors Conditions Drugs Pricing

Conditions

Chronic Atrophic Gastritis

Keywords

Chronic Atrophic GastritisStomach CancerBiomarkerMetabolomeTranscriptomeProteome

Outcome Measures

Primary Outcomes (1)

Chronic atrophic gastritis
Corpus-dominant chronic atrophic gastritis was characterized by a PGI/PGII ratio of less than 3.
1 Sep. 2020 to 31 Dec. 2021

Study Arms (2)

Participants with chronic atrophic gastritis

Corpus-dominant chronic atrophic gastritis was characterized by a PGI/PGII ratio of less than 3.

Other: Metabolomic profiling

Healthy participants

Healthy participants in the TwinGene cohort were included.

Other: Metabolomic profiling

Interventions

Metabolomic profilingOther

Metabolomic profiling using serum samples was performed based on Nightingale Blood Biomarker Analysis platform; Proteomic profiling will be performed by both Scanning SWATH and OLINK® Explore 384 Oncology panel.

Also known as: Proteomic profiling

Healthy participantsParticipants with chronic atrophic gastritis

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age46 Years - 97 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

The study population is part of the Swedish Twin Registry (STR), which collected questionnaire data from all twins born after 1886. The data in this specific study is a subset of the Screening Across the Lifespan (SALT) study within the STR, in which all twins born between 1911-1958 were interviewed between 1998-2002. The subcohort named TwinGene was set-up between the years 2004 and 2008 when participants were invited to respond to a questionnaire on common diseases and provide a blood sample.

You may qualify if:

Sponsors & Collaborators

Karolinska Institutet
Otherlead

Study Sites (1)

Karolinska Institutet

Solna, Stockholm County, 17165, Sweden

Biospecimen

Retention: SAMPLES WITH DNA

Participants from TwinGene provided blood samples.

MeSH Terms

Conditions

Gastritis, AtrophicStomach Neoplasms

Condition Hierarchy (Ancestors)

GastritisGastroenteritisGastrointestinal DiseasesDigestive System DiseasesStomach DiseasesGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasms

Enrollment

12,599 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: CROSS SECTIONAL
Target Duration: 1 Day
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Professor

Study Record Dates

First Submitted

February 12, 2024

First Posted

February 20, 2024

Study Start

January 1, 2024

Actual (reported)

Multi-omics Analyses on Etiology and Early Detection of Stomach Cancer Precursor Lesions

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Participants with chronic atrophic gastritis

Healthy participants

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Participants with chronic atrophic gastritis

Healthy participants

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations